410 research outputs found
Nitrous oxide fluxes from tropical peat with different disturbance history and management
Peer reviewe
Bioremediation of creosote contaminated soil in both laboratory and field scale: Investigating the ability of methyl-β-cyclodextrin to enhance biostimulation
© 2015 Elsevier Ltd. We investigated the bioremediation of 16 polycyclic aromatic hydrocarbons (PAH) in historically creosote contaminated soil using both laboratory and field scale experiments. We found that nutrient amendments and circulation of methyl-β-cyclodextrin (CD) solution enhanced soil microbial degradation capacity. In the laboratory experiment, the degradation of lower molecular weight, 2-3 ringed PAHs was achieved already by circulating nutrient solution and the use of CD mainly increased the desorption and removal of larger, 4-5 aromatic ringed PAH compounds. The 1% CD concentration was most feasible for bioremediation as most of the extracted PAH compounds were degraded. In the 5% CD treatment, the PAH desorption from soil was too fast compared to the degradation capacity and 25% of the total PAH amount remained in the circulated solution. Similar lab-scale results have been generated earlier, but very little has been done in full field scale, and none in freezing conditions. Although freezing stopped circulation and degradation completely during the winter, PAH degradation returned during the warm period in the field test. Circulation effectiveness was lower than in the laboratory but the improved nutrient and moisture content seemed to be the main reason for decreasing soil PAH concentrations. It also appeared that PAH extraction yield in chemical analysis was increased by the CD treatment in field conditions and the results of CD-treated and non-treated soil may therefore not be directly comparable. Therefore, a positive effect of CD on PAH degradation velocity could not be statistically confirmed in the field test. Based on our results, we recommend initiating the bioremediation of PAH contaminated soil by enhancing the microbial degradation with nutrient amendments. The CD seems to be useful only at the later stage when it increases the solubilisation of strongly absorbed contaminants to some extent. More investigation is also needed of the CD effect on the PAH yield in the chemical analysis
Late diagnoses of Dravet syndrome: How many individuals are we missing?
We report new genetic diagnoses of Dravet syndrome in a group of adults with complex epilepsy of unknown cause, under follow up at a tertiary epilepsy centre. Individuals with epilepsy and other features of unknown cause from our unit underwent whole genome sequencing through the 100,000 Genomes Project. Virtual gene panels were applied to frequency-filtered variants based on phenotype summary. Of 1078 individuals recruited, 8 (0.74%) were identified to have a pathogenic or likely pathogenic variant in SCN1A. Variant types were: nonsense (stopgain) in five (62.5%) and missense in three (37.5%). Detailed review of childhood history confirmed a phenotype compatible with Dravet syndrome. Median age at genetic diagnosis was 44.5 years (range 28-52 years). Tonic-clonic seizures were ongoing in all despite polytherapy including valproate. All had a history of fever sensitivity and myoclonic seizures, which were ongoing in two (25%) and three (37.5%) individuals, respectively. Salient features of Dravet syndrome may be less apparent in adulthood, making clinical diagnosis difficult. Regardless of age, benefits of a genetic diagnosis include access to syndrome-specific treatment options, avoidance of harmful drugs, and monitoring for common complications
Recommended from our members
Effect of Inhaled Xenon on Cerebral White Matter Damage in Comatose Survivors of Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial
IMPORTANCE: Evidence from preclinical models indicates that xenon gas can prevent the development of cerebral damage after acute global hypoxic-ischemic brain injury but, thus far, these putative neuroprotective properties have not been reported in human studies. OBJECTIVE: To determine the effect of inhaled xenon on ischemic white matter damage assessed with magnetic resonance imaging (MRI). DESIGN, SETTING, AND PARTICIPANTS: A randomized single-blind phase 2 clinical drug trial conducted between August 2009 and March 2015 at 2 multipurpose intensive care units in Finland. One hundred ten comatose patients (aged 24-76 years) who had experienced out-of-hospital cardiac arrest were randomized. INTERVENTIONS: Patients were randomly assigned to receive either inhaled xenon combined with hypothermia (33°C) for 24 hours (n = 55 in the xenon group) or hypothermia treatment alone (n = 55 in the control group). MAIN OUTCOMES AND MEASURES: The primary end point was cerebral white matter damage as evaluated by fractional anisotropy from diffusion tensor MRI scheduled to be performed between 36 and 52 hours after cardiac arrest. Secondary end points included neurological outcome assessed using the modified Rankin Scale (score 0 [no symptoms] through 6 [death]) and mortality at 6 months. RESULTS: Among the 110 randomized patients (mean age, 61.5 years; 80 men [72.7%]), all completed the study. There were MRI data from 97 patients (88.2%) a median of 53 hours (interquartile range [IQR], 47-64 hours) after cardiac arrest. The mean global fractional anisotropy values were 0.433 (SD, 0.028) in the xenon group and 0.419 (SD, 0.033) in the control group. The age-, sex-, and site-adjusted mean global fractional anisotropy value was 3.8% higher (95% CI, 1.1%-6.4%) in the xenon group (adjusted mean difference, 0.016 [95% CI, 0.005-0.027], P = .006). At 6 months, 75 patients (68.2%) were alive. Secondary end points at 6 months did not reveal statistically significant differences between the groups. In ordinal analysis of the modified Rankin Scale, the median (IQR) value was 1 (1-6) in the xenon group and 1 (0-6) in the control group (median difference, 0 [95% CI, 0-0]; P = .68). The 6-month mortality rate was 27.3% (15/55) in the xenon group and 34.5% (19/55) in the control group (adjusted hazard ratio, 0.49 [95% CI, 0.23-1.01]; P = .053). CONCLUSIONS AND RELEVANCE: Among comatose survivors of out-of-hospital cardiac arrest, inhaled xenon combined with hypothermia compared with hypothermia alone resulted in less white matter damage as measured by fractional anisotropy of diffusion tensor MRI. However, there was no statistically significant difference in neurological outcomes or mortality at 6 months. These preliminary findings require further evaluation in an adequately powered clinical trial designed to assess clinical outcomes associated with inhaled xenon among survivors of out-of-hospital cardiac arrest. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00879892
- …